You are here

Generic Version of Klonopin Approved

WOODCLIFF LAKE, N.J., Aug. 11 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market Clonazepam Orally Disintegrating Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg & 2 mg, the generic equivalent of Hoffman La Roche's Klonopin(R) Wafers. The Company plans to launch its product immediately.

Klonopin (Clonazepam) is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures, and, for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV.

Source: Barr Pharmaceuticals, Inc

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs